文献速递消化道肿瘤与早癌消化内镜

按CDH1突变状态比较遗传性弥漫性胃癌的内镜监测研究

Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status.
PubMed 文献 · Gastrointest Endosc · 2017-07-06

这项前瞻性纵向队列研究纳入85例符合遗传性弥漫性胃癌(HDGC)标准的个体,共进行201次内镜监测,比较CDH1突变携带者与非携带者检出印戒细胞癌(SRCC)病灶的检出率及随时间变化。CDH1突变携带者SRCC检出率为61.1%,非携带者为9.7%,突变阳性者内镜下检出SRCC的风险约为无突变者的10倍(P < .0005);随监测次数增加SRCC检出率明显下降,监测与心理健康改善相关。

要点

  • CDH1突变携带者SRCC检出率61.1%,非携带者9.7%,突变阳性者检出风险约为无突变者的10倍(P < .0005)。
  • 采用标准化多点活检方案可在内镜下检出CDH1突变携带者的SRCC病灶。
  • 随后的内镜检查中SRCC检出率明显下降,提示可考虑降低内镜监测频率。

核心结论

  • SRCC病灶在CDH1突变携带者中常见,采用标准化多点活检方案可在内镜下检出。
  • SRCC检出率随时间下降,提示内镜监测频率可能可以降低。
  • 对于未检出CDH1致病性变异的患者,鉴于检出率低,需评估成本效益比。

研究设计与样本

  • 前瞻性纵向队列研究,纳入符合HDGC标准的患者,按严格方案行内镜监测(先视诊,再行局灶病变活检与随机活检以检出SRCC病灶)。
  • 共85例符合HDGC标准的个体接受201次内镜检查,其中54例(63.5%)CDH1突变检测阳性。
  • 采用生存分析按CDH1突变状态评估SRCC检出的进展,并以欧洲癌症研究与治疗组织生活质量问卷核心30项及36项简表健康调查在监测前及每次内镜检查时评估生活质量。

主要发现

  • CDH1突变携带者SRCC检出率为61.1%,非携带者为9.7%。
  • 突变阳性患者内镜下检出SRCC的风险约为未检出突变者的10倍(P < .0005)。
  • 随后的内镜检查中SRCC检出率明显下降。
  • 监测与心理健康改善相关。

临床怎么用

  • 对CDH1突变携带者可采用标准化多点活检方案行内镜监测以检出SRCC病灶。
  • SRCC检出率随监测次数下降,提示内镜监测频率可能可以降低。
  • 对未检出CDH1致病性变异的患者,鉴于检出率低,需评估成本效益比。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Hereditary diffuse gastric cancer (HDGC) accounts for 1% of gastric cancer cases. For patients with a germline CDH1 mutation, risk-reducing gastrectomy is recommended. However, for those delaying surgery or for families with no causative mutation identified, regular endoscopy is advised. This study aimed to determine the yield of signet ring cell carcinoma (SRCC) foci in individuals with a CDH1 pathogenic variant compared with those without and how this varies with successive endoscopies. METHODS: Patients fulfilling HDGC criteria were recruited to a prospective longitudinal cohort study. Endoscopy was performed according to a strict protocol with visual inspection followed by focal lesion and random biopsy sampling to detect foci of SRCC. Survival analysis determined progression to finding of SRCC according to CDH1 mutation status. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and 36-item Short Form Health Survey questionnaires assessed quality of life before surveillance and each endoscopy. RESULTS: Eighty-five individuals fulfilling HDGC criteria underwent 201 endoscopies; 54 (63.5%) tested positive for CDH1 mutation. SRCC yield was 61.1% in CDH1 mutation carriers compared with 9.7% in noncarriers, and mutation-positive patients had a 10-fold risk of SRCC on endoscopy compared with those with no mutation detected (P < .0005). Yield of SRCC decreased substantially with subsequent endoscopies. Surveillance was associated with improved psychological health. CONCLUSIONS: SRCC foci are prevalent in CDH1 mutation carriers and can be detected at endoscopy using a standardized, multiple biopsy sampling protocol. Decreasing yield over time suggests that the frequency of endoscopy might be reduced. For patients with no CDH1 pathogenic variant detected, the cost-to-benefit ratio needs to be assessed in view of the low yield.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Mi EZ, Mi EZ, di Pietro M, et al. Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status. Gastrointest Endosc. 2017. PMID: 28688938. doi:10.1016/j.gie.2017.06.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。